Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
about
Immunotherapy and radiation therapy for malignant pleural mesothelioma.Immune Checkpoint Inhibition and the Prevalence of Autoimmune Disorders Among Patients With Lung and Renal Cancer.Autoimmune Hemolytic Anemia as a Complication of Nivolumab Therapy.Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockadeFrom targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.Optimizing tumor immune response through combination of radiation and immunotherapy.Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: A systematic review of the literature.Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.Carcinogenesis and therapeutics: the microbiota perspective.Otorhinolaryngological Toxicities of New Drugs in Oncology.Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma.Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.Adverse Events in Cancer Immunotherapy.Control of NK Cell Activation by Immune Checkpoint Molecules.Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.CD4 and CD8 T lymphocyte interplay in controlling tumor growth.Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.Endocrinopathies with use of cancer immunotherapies.Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors.Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses.Emerging biomarkers for cancer immunotherapy in melanoma.Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab.Acute inflammatory thyromegaly following checkpoint inhibition: A new imaging entity?Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis.Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.Autoimmune Diabetes Associated With Pembrolizumab: A Review of Published Case Reports.Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abataceptBilateral anterior uveitis after immunotherapy for malignant melanomaDevelopment of shellfish allergy after exposure to dual immune checkpoint blockade
P2860
Q33645613-1E8C721E-5E57-43BE-A9DA-DCC5657BCC13Q33764931-CBC3AF38-5364-4256-821C-A9652F10087FQ36213970-8210EC51-F850-4161-96DE-311B20537355Q36370614-11381DFB-7D98-4B32-94F5-BFBF1D56F0F7Q37642460-C80DF5B8-5F61-4197-B7EE-5142FE14BBA1Q38614781-FCC28920-558C-41F4-8625-631077EA634AQ38687631-65FE4CE1-E314-4003-90D4-E455F679A6C4Q38819982-E6D84712-9174-42BF-A866-13865B5255EEQ38826536-C6099FE5-4D47-45E8-8EBF-AB3B7ACE62B5Q39044741-C3BBBE71-331C-400B-9585-64ABAFAD08E5Q39085984-5E1789B8-0A87-420D-8D67-9E25E40522FFQ39146396-8E4BE44B-82F6-4D28-BB8C-623E6CE0EADFQ39185692-8EAACE1E-20C6-4FC8-AD59-F03B7C9B5423Q39402079-ECBAAB64-A77E-493A-B010-4F75AFFD8DFCQ42094902-9872F6C8-1405-42AC-A90D-7794275A5A50Q42688279-C9753E8A-4642-48F7-8A1F-0A1F562116DDQ46884498-04E00C07-3371-4374-B773-4E78AC0F2C64Q47128718-84E3CAAD-C9FF-4318-9ED7-78DACE4BADE5Q47211203-DAAB0769-A671-446D-BD0E-7AEE5B8B0F66Q47277879-A4D9314F-5BC0-46B7-856A-6592F548879DQ47287952-F2B1934A-D0F0-4C04-A139-F7642416DF7CQ47304240-A95099A6-8FCA-4C19-A515-8B5D9B118171Q48185876-EAB91551-19A0-4633-9A50-2D6CCCC1AA9CQ48190615-5CFBDE77-EA3E-4150-8F18-0B958EEC9297Q48300545-7DFC1028-52CF-4872-A1C2-9C4957757644Q49231401-C15BC325-3426-4C2A-91ED-FF36D5D92B80Q49342746-1F9D68C7-215C-496A-9440-9F878E9A14BFQ49679207-D697B0CB-115A-48D8-9FCC-8F73E1BDCEACQ50058145-7781A501-F8E7-4006-9717-FB9C9B307802Q50086190-CB0CD10F-7229-402C-AC36-3992EFDCE244Q50143789-2BF04A77-4D81-4976-8310-5A636E9C37C4Q50347153-AE27F193-50C6-45E7-8528-04EF4A0BC820Q52649639-BCEB8325-6099-4AB4-818D-70C8361C2CA9Q52655558-C43D1A01-AD78-4C23-861A-F81D0E1F3416Q53695267-2A74C5BB-F8FE-44AF-99B8-05AA4E004233Q54966985-CAE6C3D1-6B9A-48B8-9DF7-FD7908D5FD92Q55110249-BA475173-E5FC-42B0-9CEC-2D374755B620Q56890042-816C7957-1C38-48BB-B0DF-E41AD6B0F821Q57193038-7D031614-4E9B-43D7-999F-B138C02A696BQ57301432-7AE970FE-24EB-453A-9E7D-540B01862BCF
P2860
Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Adverse Events Associated with ...... tematic Review of Case Reports
@ast
Adverse Events Associated with ...... tematic Review of Case Reports
@en
Adverse Events Associated with ...... tematic Review of Case Reports
@nl
type
label
Adverse Events Associated with ...... tematic Review of Case Reports
@ast
Adverse Events Associated with ...... tematic Review of Case Reports
@en
Adverse Events Associated with ...... tematic Review of Case Reports
@nl
prefLabel
Adverse Events Associated with ...... tematic Review of Case Reports
@ast
Adverse Events Associated with ...... tematic Review of Case Reports
@en
Adverse Events Associated with ...... tematic Review of Case Reports
@nl
P2860
P31
P3181
P1433
P1476
Adverse Events Associated with ...... tematic Review of Case Reports
@en
P2093
Maria E Suarez-Almazor
Noha Abdel-Wahab
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0160221
P407
P50
P5008
P577
2016-07-29T00:00:00Z